Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock Position Raised by New York State Teachers Retirement System

New York State Teachers Retirement System lifted its stake in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 2.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,693 shares of the company’s stock after acquiring an additional 809 shares during the quarter. New York State Teachers Retirement System owned 0.06% of Harmony Biosciences worth $1,091,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of HRMY. GAMMA Investing LLC boosted its position in shares of Harmony Biosciences by 92.6% in the fourth quarter. GAMMA Investing LLC now owns 907 shares of the company’s stock worth $31,000 after buying an additional 436 shares during the period. Mendota Financial Group LLC boosted its position in shares of Harmony Biosciences by 24,125.0% in the fourth quarter. Mendota Financial Group LLC now owns 969 shares of the company’s stock worth $33,000 after buying an additional 965 shares during the period. CWM LLC boosted its position in shares of Harmony Biosciences by 111.7% in the third quarter. CWM LLC now owns 1,469 shares of the company’s stock worth $59,000 after buying an additional 775 shares during the period. KBC Group NV boosted its position in shares of Harmony Biosciences by 79.9% in the fourth quarter. KBC Group NV now owns 1,844 shares of the company’s stock worth $63,000 after buying an additional 819 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in shares of Harmony Biosciences in the third quarter worth $74,000. 86.23% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Needham & Company LLC decreased their target price on Harmony Biosciences from $52.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, February 19th. HC Wainwright reissued a “buy” rating and set a $75.00 price objective on shares of Harmony Biosciences in a research report on Wednesday, February 19th. Oppenheimer reissued an “outperform” rating and set a $59.00 price objective (up previously from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Mizuho reduced their price objective on Harmony Biosciences from $52.00 to $42.00 and set an “outperform” rating for the company in a research report on Thursday. Finally, Cantor Fitzgerald lifted their price objective on Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Harmony Biosciences has a consensus rating of “Buy” and an average target price of $53.67.

Harmony Biosciences Stock Down 0.9 %

Shares of HRMY opened at $34.56 on Monday. The company has a market capitalization of $1.97 billion, a P/E ratio of 16.38, a PEG ratio of 0.47 and a beta of 0.80. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. Harmony Biosciences Holdings, Inc. has a one year low of $28.14 and a one year high of $41.61. The business’s 50 day simple moving average is $36.57 and its 200-day simple moving average is $35.81.

Insider Buying and Selling

In related news, CEO Jeffrey M. Dayno sold 19,293 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.13, for a total value of $774,228.09. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jeffrey Dierks sold 1,123 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.00, for a total transaction of $44,920.00. The disclosure for this sale can be found here. Insiders sold 72,452 shares of company stock worth $2,831,679 in the last quarter. Insiders own 30.80% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.